Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a efinopegdutide in compensated cirrhosis due to MASH
jRCT2031240217Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
01
Overview
Phase 2, randomised, double-blind trial in Cirrhosis and metabolic dysfunction-associated steatohepatitis (MASH) comparing Efinopegdutide with Placebo (2 arms). Primary endpoints: Change from Baseline in Liver Fat Content (LFC) at Week 28, Percentage of Participants Who Experienced an Adverse Event (AE) and 1 more. Started Aug 2024; status: active, not recruiting.
02
Drugs
efinopegdutide
03
Conditions
Cirrhosismetabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on jRCT2031240217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240217.